Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dynavax Technologies (DVAX)
8.88 ? -1.24 (-12.25%)
Volume: 7,274,183 @07/24/20 7:59:49 PM EDT
Bid Ask Day's Range
9.03 9.05 8.8 - 9.86
DVAX Detailed Quote
Janssen Robert just killed the momentum by disposing some of his shares but big thanks to him I was able to add more today..
$DVAX There are no approved universal flu vaccines. The effectiveness of seasonal influenza vaccine ranges between 10% and 60%. A universal vaccine could eliminate the need to update and administer the seasonal flu vaccine annually and could protect against newly emerging flu strains, potentially including those that could cause a flu pandemic.
“We are focused on designing novel vaccine candidates and delivery platforms with an emphasis on cross-protective vaccine strategies that could be used in healthy adults as well as populations at high risk for the most serious outcomes of influenza, such as children, older adults, and pregnant women,” said Peter Palese, PhD, Professor and Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. “Including CpG 1018 in these vaccines gives us an important tool to potentially improve the immune response, especially in populations that need it most like the elderly.”
$DVAX Dynavax Technologies (DVAX)
11.7 ? 0.33 (2.90%)
Volume: 7,338,802 @07/20/20 7:50:40 PM EDT
Bid Ask Day's Range
11.78 11.85 11.23 - 12.44
DVAX Detailed Quote
Looking good pre-market $20 Target price today *DVAX*
Pre-earnings Bullish Momentum Pattern and Trigger in Dynavax Technologies Corp
https://www.cmlviz.com/2020/07/19/DVAX/pre-earnings-bullish-momentum-pattern-and-trigger-in-dynavax-technologies-corp.html
$DVAX READING, INTERESTING
RE;
Big moves upward in all COVID-19 stocks. GLTA!
Big moves upward in all COVID-19 stocks. GLTA!
$DVAX OUTSTANDING THANK YOU
$DVAX Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant GlobeNewswire Inc. - 7/16/2020 8:40:10 AM
$DVAX Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with ... GlobeNewswire Inc. - 7/14/2020 8:00:10 AM
$DVAX Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with ... GlobeNewswire Inc. - 7/10/2020 4:01:10 PM
Dynavax et Medicago annoncent une collaboration pour développer un nouveau candidat vaccin avec adjuvant contre la COVID-19 PR Newswire (Canada) - 7/8/2020 9:32:00 AM
$DVAX Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 7/2/2020 5:37:09 PM
Dynavax to Present at the H.C. Wainwright Virtual Fireside Chat Series GlobeNewswire Inc. - 6/22/2020 9:00:10 AM
$DVAX Dynavax Technologies (DVAX)
11.37 ? 1.88 (19.81%)
Volume: 26,794,357 @07/17/20 7:59:43 PM EDT
Bid Ask Day's Range
11.26 11.29 9.5 - 12.19
DVAX Detailed Quote
$DVAX IS DIS TRUE ?????
Holy moly DVAX $100 TARGET PRICE WOW!
WOW!*DVAX*WOW!*****WOOHOO$$$ to SPCE in a UFO
* * $DVAX Video Chart 07-17-2020 * *
Link to Video - click here to watch the technical chart video
Good news today..GO DVAX! long over due..
Absolutely *DVAX*
DVAX you're looking at the next Coronavirus big winner stock $100 TARGET price.
bahahahaha WOOHOOOOOOO DVAX THE NEXT NVAX WOW!
keep loading before it gets to 7
Loading up here DVAX $25 TARGET PRICE WOOHOOOOOOOOOOOOOOO
News: $DVAX Here's Why Dynavax Is Surging 6.1% Today
Dynavax 's (NASDAQ: DVAX) shares are climbing 6.1% as of 3:35 p.m. EDT on Tuesday after the company announced the first patients have been dosed in an early stage trial evaluating a COVID-19 vaccine containing its CpG 1018 adjuvant. Medicago, a private company owned by Mitsubishi Tanabe Pha...
Find out more DVAX - Here's Why Dynavax Is Surging 6.1% Today
News: $DVAX Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago's COVID-19 Vaccine Candidate with Dynavax's CpG 1018 Adjuvant
Medicago expects to enroll 180 healthy adult participants Preliminary safety and immunogenicity results are expected in October 2020 Dynavax is providing CpG 1018, the adjuvant contained in its U.S. FDA-approved adult hepatitis B vaccine, to enhance the immune response of Medicagoȁ...
Got this from DVAX - Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago's COVID-19 Vaccine Candidate with Dynavax's CpG 1018 Adjuvant
Currently have 6 COVID 19 STOCKS
DVAX
MRNA
NVAX
VXRT
IBIO
SRNR
Looking for 4 more !
MIGHT BE GOOD BUY.
EPS = -2.18
Wedge formation this morning on decent volume. Looks like about to break out through $10.
DVAX$$$ $15 TARGET PRICE WOOHOOOOOOOOOOOOOOO
More sells than buys today. But we are still up, have a great weekend.
Happy Trading:)
When trading timing is imperative. I added more on the dip yesterday.
Happy Trading :)
I learned to trade DVAX in and out by following the trend that's been happening as of late. So far so good
Nothing to worry about, today was a nice healthy pullback.
Happy Trading :)
A healthy pullback would be nice to keep the share price stable.
Been on my radar for the past couple weeks.
Stocks not going back down look at all that buying that happened last week.woohooooo DVAX$$$$$ $15 Target price tomorrow
I agree a dip back to $7ish is a healthy one
This run will get sold off so fast it will make your eyes water and your teeth rot...technically too fast
Followers
|
108
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2538
|
Created
|
10/09/06
|
Type
|
Free
|
Moderators |
We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.
HEPLISAV-B®
[HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED]
During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas
– these include safeguarding the health and safety of our employees and customers; continuing effective operations
to ensure patient access to HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]; maintaining our financial strength and stability;
and supporting efforts to develop a COVID-19 vaccine.
Shs Outstand | 85.48M |
Shs Float | 84.14M |
Short Float | 18.11% |
Debt/Eq | 15.22 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |